A Phase 1/2 interventional study of Tecnis implant and ReSTOR implant in Cataract and Astigmatism, sponsored by University of Sao Paulo. Completed at 1 site in Brazil. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2010-07-02.
Sponsored by University of Sao Paulo · Phase 1/2, Interventional, and Treatment
The purpose of this study is to determine if differences in the design of multifocal intra-ocular lenses would mean different values of higher-order aberrations and different performance in objective parameters such as modulation transfer function.
1,726 studies on the registry are indexed under Cataract; 230 are open to participants now.
This study's planned enrollment of 60 is below the median of 80 across 1,171 interventional studies indexed under Cataract.
Browse Cataract studies →University of Sao Paulo is the lead sponsor of 1,030 studies on the registry; 92 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any ocular diseases, such as:
Device: Tecnis implant
Device: ReSTOR implant
Device: ReZoom implant
Implant of diffractive multifocal IOL Tecnis
Implant of multifocal IOL ReSTOR
Implant of multifocal IOL ReZoom
visual acuity, wavefront data and modulation transfer function
Time frame: 30, 90 and 120 days after surgery
contrast sensitivity
Time frame: 90 days after surgery
This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.